Shares of Dow Chemical Co (NYSE:DOW), inclined 0.83% to $47.47, during its last trading session. In the last trading session, the stock moved on high volume, trading at a volume of 32.90 M as compared to its average daily volume of 16.95 million shares.
The stock, as of recent close, has shown weekly upbeat performance of 12.00% which was maintained at 8.79% in 1-month period.
Dow Chemical CFO Howard Ungerleider is a strong believer in developing a value-based culture inside the finance function. According to Business Insider
The Dow Chemical Company is a global material science company with 2014 annual sales of more than $58 billion.
Ungerleider joined Dow in 1990, and his career with the company has spanned a wide variety of commercial, business, financial, geographic, functional, and enterprise-level leadership roles.
His advice is simple but also highly effective. “In this more volatile macroeconomic environment, finance organizations hold a noteworthy leadership role in developing true value-based cultures,” Ungerleider said. “It starts with a strong accountability focus within the organization — a clear understanding of value drivers, coupled with scorecards based on common financial metrics.” Business Insider
The Dow Chemical Company manufactures and supplies products that are used primarily as raw materials in the manufacture of customer products and services worldwide. It operates through Agricultural Sciences, Consumer Solutions, Infrastructure Solutions, Performance Materials & Chemicals, and Performance Plastics segments.
On Wednesday, Shares of Yahoo! Inc. (NASDAQ:YHOO), gained 2.96% to $31.87. The stock attained the volume of 12.22 million shares.
The year-to-date (YTD) performance reflected a -36.90% below last year. During the past month the stock gains 3.14%, bringing three-month performance to -15.26% and six-month performance to -30.16%. The stock holds the market capitalization of 30.00B.
Yahoo! Inc. YHOO declared that it is expanding its data center in Quincy, Washington, to meet the growing demand for Internet and data storage. The extended data center is planned to open next summer. According to Zacks
Yahoo! is stepping up its investments in data centers in the area. The company had opened this data center in 2007 and the extension is predictable to add about 300,000 square feet to the facility. Such large-scale expansion will also create additional positions.
Meanwhile, the growing demand for cloud computing and Internet is in turn propelling demand for data centers. Market research firm IDC predicts that the cloud market will skyrocket 130% to $43.0 billion in 2016. Data centers comprise large banks with computer servers that process Internet searches, emails, videos in addition to other such services. Zacks
Yahoo! Inc. provides search and display advertising services on Yahoo properties and associate sites worldwide. The company offers Yahoo Search that serves as a starting point to navigate the Internet and discover information; and Yahoo Answers, which enables users to seek, discover, and share knowledge and opinions across mobile phones, tablets, and desktops.
Shares of Bristol-Myers Squibb Co (NYSE:BMY), inclined 1.12% to $60.55, during its last trading session. In the last trading session, the stock moved on low volume, trading at a volume of 8.24 M as compared to its average daily volume of 8.96 million shares.
The stock, as of recent close, has shown weekly upbeat performance of 2.28% which was maintained at 3.29% in 1-month period.
Seattle Genetics, Inc. (Nasdaq:SGEN) declared that it has initiated a phase 1/2 clinical trial of ADCETRIS (brentuximab vedotin) in combination with Opdivo (nivolumab) for patients with relapsed or refractory Hodgkin lymphoma (HL) after failure of frontline treatment. The trial is being conducted under a formerly declared clinical trial partnershipagreement with Bristol-Myers Squibb Company (BMY). ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, a defining marker of classical HL, which combines the targeting ability of a monoclonal antibody with a highly potent cell-killing agent. Opdivo is a human antibody that targets and inhibits the programmed death receptor-1 (PD-1), resulting in T-cell activation. Opdivo is part of a new class of cancer immunotherapy treatments known as checkpoint inhibitors, which are designed to harness the body’s own immune system in fighting cancer by targeting distinct regulatory components of the immune system. A second trial under the partnershipis planned to start later in 2015 for relapsed or refractory B-cell and T-cell non-Hodgkin lymphoma (NHL), counting diffuse large B-cell lymphoma (DLBCL).
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
